Stockreport

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) [Yahoo! Finance]

UCB SA UNSP/ADR  (UCBJY) 
NASDAQ:AMEX Investor Relations: ucb.com/investors
PDF Neurology published results from a multicenter retrospective chart review study of pyrimidine nucleoside and/or nucleotide therapy which showed a reduction in the risk [Read more]